18 March 2026 in Infectious Diseases in Clinical Practice
Managing chronic hepatitis B in children presents significant challenges, particularly due to the risk of antiviral resistance with prolonged lamivudine use. We report 3 pediatric cases in Vietnam who experienced virologic breakthrough after lamivudine therapy failure. Genotypic testing of the hepatitis B virus polymerase gene revealed resistance mutations: M204V/I in all 3 cases, L180M in 2 cases (cases 2 and 3), L80I in case 1, and M250L in case 2. After resistance was identified, switching to tenofovir disoproxil fumarate achieved complete viral suppression, whereas switching to entecavir resulted in a partial yet clinically meaningful virologic response, due to cross-resistance conferred by the M204V/I mutations. These cases provide clinical observations from a resource-limited setting, suggesting that tenofovir disoproxil fumarate may be preferable to entecavir for salvage therapy following lamivudine failure. This emphasizes the urgent need for accessible genotypic testing to guide treatment decisions and prevent the use of ineffective sequential monotherapies.
12 June 2026 in JAIDS Journal of Acquired Immune Deficiency Syndromes
CPChatkamol Pheerapanyawaranun
Chatkamol Pheerapanyawaranun
OAon behalf of the TREAT Asia Pediatric HIV Observational Database of IeDEA Asia-Pacific
on behalf of the TREAT Asia Pediatric HIV Observational Database of IeDEA Asia-Pacific
+15
Background: Transitioning from pediatric to adult HIV care is critical for adolescents and young adults living with HIV (AYLH). This study assessed the timing and factors associated with this transition in Asia. Setting: Retrospective study of AYLH enrolled in TREAT Asia Pediatric HIV Observational Database clinics between May 1991–December 2020. Methods: Eligible AYLH were categorized into 18-year-old transitions or continued pediatric care. Excluding AYLH who remained in pediatric care, median age at transition was 16.1 years (IQR: 14.9–17.0) for <18-year-old transitions and 20.0 years (IQR: 19.1–21.2) for ≥18-year-old transitions. At age 18, among 1,368 AYLH with available viral load data, 72.9% (n=998) had viral loads <50 copies/mL (78.9% in <18-year-old transitions [n=310/393] vs 70.6% in ≥18-year-old transitions [n=688/975]; P =0.002). Median CD4 count was 635 cells/μL (IQR: 450–842). Factors independently associated with transitions at ≥18 years old or continued pediatric care included residence in a high-middle-income country (aOR 10.68 [95%CI: 7.76, 14.68], P <0.001), living with family (aOR 2.81 [95%CI: 1.99, 3.97], P <0.001), and prior ART class switching (aOR 1.91 [95%CI: 1.34, 2.72], P <0.001). Conclusion: Most AYLH in this cohort transitioned at ≥18. About one-fourth had unsuppressed viral loads at age 18, irrespective of transition status, underscoring the need for personalized treatment approaches that support ART adherence from pediatric care, preparing AYLH for transition to adult clinics.